Hi there Maxkieh,
What timeframe was this target price?
Although I love ARX and its management, the company is not well supported/ known by the ASX investors. Perhaps because it is a NZ company it doesn't attract the same fan base that PNV does.
At $11.00 per share, this would equate to a valuation of over $3.00b for ARX. This is unlikely in the next couple of years. I would love to be proved wrong though. Even PNV currently only has a market cap of $1.86b on similar sales revenue.
PNV forward sales revenue growth and gross margins are superior to ARX.
Bell Potter offer a more realistic price target of around $2.10 for ARX.
News: ARX Aroa Biosurgery Posts FY22 Product Sales Guidance Of $30M-33M, page-7
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.0¢ |
Change
-0.005(1.03%) |
Mkt cap ! $165.5M | |||
| Open | High | Low | Value | Volume |
| 49.0¢ | 49.0¢ | 47.0¢ | $200.4K | 417.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18117 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 45295 | 3 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| ARX (ASX) Chart |